Instant Report
FDF

Date: 11-Oct-2021

Aurobindo Pharma, MSN Labs Seek DGCI Nod For Phase-III Trials Of Mercks Molnupiravir

Last week, Aurobindo Pharma and MSN Laboratories presented the interim clinical trial data in moderate patients before the the Subject subject expert committee (SEC) — the expert panel under the Drug Controller General of India (DCGI).

Two Indian pharmaceutical companies have sought permission from India’s drug regulator to continue phase III trials on antiviral drug molnupiravir in mild Covid patient. US firm Merck & Co’s experimental antiviral drug molnupiravir is touted to become first antiviral drug to treat Covid-19.

Last week, Aurobindo Pharma and MSN Laboratories presented the interim clinical trial data in moderate patients before the the Subject subject expert committee (SEC) — the expert panel under the Drug Controller General of India (DCGI). The SEC advises the drug regulator on applications seeking approvals for new vaccines, drugs and clinical trials in India.

In a meeting held on October 4, both the companies said that they “they want to discontinue phase III trial in moderate Covid-19 patients and continue the phase III trial in mild Covid patients", as per the minutes of the meeting. ET has seen the minutes of the SEC meeting.